TwinBeech Capital’s Immunogen Inc IMGN Stock Holding History

TwinBeech Capital’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-28,117	Closed	-$185K	–	807
2021 Q2	$185K	Buy	+28,117	New	+$196K	0.02%	419

Other funds holding IMGN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

TwinBeech Capital's IMGN Position: Q3 2021 in Review

TwinBeech Capital sold out of Immunogen Inc (IMGN) in Q3 2021, closing a stake of 28,117 shares — an estimated $185K sold.

TwinBeech Capital first reported a position in IMGN in Q2 2021 and held it in 1 quarter. The position peaked at $185K in Q2 2021. 217 funds tracked by Wall St. Rank hold IMGN as of Q3 2021.

TwinBeech Capital reported no remaining Immunogen Inc position as of Q3 2021 after selling out during the quarter.
TwinBeech Capital sold 28,117 Immunogen Inc shares in Q3 2021, an estimated $185K.
TwinBeech Capital first reported a position in Immunogen Inc in Q2 2021 and held it in 1 quarter.
TwinBeech Capital's Immunogen Inc position peaked at $185K in Q2 2021.
217 funds tracked by Wall St. Rank held Immunogen Inc as of Q3 2021.

Based on TwinBeech Capital's 13F filing for Q3 2021, filed 15 Nov 2021.